journal
Journals Metabolism: Clinical and Exper...

Metabolism: Clinical and Experimental

https://read.qxmd.com/read/38631460/glucagon-augments-the-secretion-of-fgf21-and-gdf15-in-masld-by-indirect-mechanisms
#1
JOURNAL ARTICLE
Michael M Richter, Ida M Kemp, Sara Heebøll, Marie Winther-Sørensen, Sasha A S Kjeldsen, Nicole J Jensen, Janus D Nybing, Frederik H Linden, Erik Høgh-Schmidt, Mikael P Boesen, Sten Madsbad, Frank Vinholt Schiødt, Kirsten Nørgaard, Signe Schmidt, Lise Lotte Gluud, Steen B Haugaard, Jens J Holst, Søren Nielsen, Jørgen Rungby, Nicolai J Wewer Albrechtsen
INTRODUCTION: Glucagon receptor agonism is currently explored for the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The metabolic effects of glucagon receptor agonism may in part be mediated by increases in circulating levels of Fibroblast Growth Factor 21 (FGF21) and Growth Differentiation Factor 15 (GDF15). The effect of glucagon agonism on FGF21 and GDF15 levels remains uncertain, especially in the context of elevated insulin levels commonly observed in metabolic diseases...
April 15, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38622040/corrigendum-to-imeglimin-improves-systemic-metabolism-by-targeting-brown-adipose-tissue-and-gut-microbiota-in-obese-model-mice-metabolism-153-april-2024-155796
#2
Motoharu Awazawa, Maya Matsushita, Ikumi Nomura, Naoki Kobayashi, Miwa Tamura-Nakano, Yuriko Sorimachi, Keiyo Takubo, Kohjiro Ueki
No abstract text is available yet for this article.
April 15, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38615945/hepatic-klf10-fh1-axis-promotes-exercise-mediated-amelioration-of-nash-in-mice
#3
JOURNAL ARTICLE
Hong-Yang Luo, Wang-Jing Mu, Min Chen, Jie-Ying Zhu, Yang Li, Shan Li, Lin-Jing Yan, Ruo-Ying Li, Meng-Ting Yin, Xin Li, Hu-Min Chen, Liang Guo
Exercise is an effective non-pharmacological strategy for the treatment of nonalcoholic steatohepatitis (NASH), but the underlying mechanism needs further investigation. Kruppel-like factor 10 (Klf10) is a transcriptional factor that is expressed in multiple tissues including liver, whose role in NASH is not well defined. In our study, exercise induces hepatic Klf10 expression through the cAMP/PKA/CREB pathway. Hepatocyte-specific knockout of Klf10 (Klf10LKO ) increases lipid accumulation, cell death, inflammation and fibrosis in NASH diet-fed mice and reduces the protective effects of treadmill exercise against NASH, while hepatocyte-specific overexpression of Klf10 (Klf10LTG ) works in concert with exercise to reduce NASH in mice...
April 12, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38609039/role-of-mitochondria-in-pathogenesis-and-therapy-of-renal-fibrosis
#4
REVIEW
Xiaodong Zhao, Yunkuo Li, Jinyu Yu, Haolin Teng, Shouwang Wu, Yishu Wang, Honglan Zhou, Faping Li
Renal fibrosis, specifically tubulointerstitial fibrosis, represents the predominant pathological consequence observed in the context of progressive chronic kidney conditions. The pathogenesis of renal fibrosis encompasses a multifaceted interplay of mechanisms, including but not limited to interstitial fibroblast proliferation, activation, augmented production of extracellular matrix (ECM) components, and impaired ECM degradation. Notably, mitochondria, the intracellular organelles responsible for orchestrating biological oxidation processes in mammalian cells, assume a pivotal role within this intricate milieu...
April 10, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38609038/deciphering-the-molecular-pathways-of-saroglitazar-a-dual-ppar-%C3%AE-%C3%AE-agonist-for-managing-metabolic-nafld
#5
REVIEW
Devaraj Ezhilarasan
Saroglitazar (SARO), a dual peroxisome proliferator activated receptor (PPAR)-α/γ agonist, has been used to treat metabolic diseases such as insulin resistance and diabetic dyslipidemia in patients with non-alcoholic fatty liver disease (NAFLD). SARO, administered at a dose of 4 mg/day, has been consistently studied in clinical trials with different time points ranging from 4 to 24 weeks with NAFLD patients. Due to its PPAR-γ agonistic action, SARO prevents adipose tissue-mediated fatty acid delivery to the liver by increasing insulin sensitivity and regulating adiponectin and leptin levels in adipose tissue...
April 10, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38609037/myeloid-trem2-ameliorates-the-progression-of-metabolic-dysfunction-associated-steatotic-liver-disease-by-regulating-macrophage-pyroptosis-and-inflammation-resolution
#6
JOURNAL ARTICLE
Wenjie Yu, Yu Zhang, Linfeng Sun, Wei Huang, Xiangdong Li, Nan Xia, Xuejiao Chen, Likalamu Pascalia Wikana, Yuhao Xiao, Minhao Chen, Sheng Han, Ziyi Wang, Liyong Pu
BACKGROUND: The prevalence of Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing year by year and has become one of the leading causes of end-stage liver disease worldwide. Triggering Receptor Expressed on Myeloid Cells 2 (Trem2) has been confirmed to play an essential role in the progression of MASLD, but its specific mechanism still needs to be clarified. This study aims to explore the role and mechanism of Trem2 in MASLD. METHODS: Human liver tissues were obtained from patients with MASLD and controls...
April 10, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38599278/baseline-phenotypes-with-preserved-%C3%AE-cell-function-and-high-insulin-concentrations-have-the-best-improvements-in-glucose-tolerance-after-weight-loss-results-from-the-prospective-dexlife-and-egir-risc-studies
#7
JOURNAL ARTICLE
S Sabatini, J J Nolan, G O'Donoghue, A Kennedy, John Petrie, Mark Walker, D J O'Gorman, A Gastaldelli
BACKGROUND: Weight loss and lifestyle intervention improve glucose tolerance delaying the onset of type 2 diabetes (T2D), but individual responses are highly variable. Determining the predictive factors linked to the beneficial effects of weight loss on glucose tolerance could provide tools for individualized prevention plans. Thus, the aim was to investigate the relationship between pre-intervention values of insulin sensitivity and secretion and the improvement in glucose metabolism after weight loss...
April 8, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38582490/kr%C3%A3-ppel-like-factor-10-protects-against-metabolic-dysfunction-associated-steatohepatitis-by-regulating-hnf4%C3%AE-mediated-metabolic-pathways
#8
JOURNAL ARTICLE
Xiaoli Pan, Shuwei Hu, Yanyong Xu, Raja Gopoju, Yingdong Zhu, Fathima N Cassim Bawa, Hui Wang, Jiayou Wang, Zaid Batayneh, Alyssa Clark, Yuhao Zeng, Li Lin, Xinwen Wang, Liya Yin, Yanqiao Zhang
BACKGROUND: Krüppel-like factor 10 (KLF10), a zinc finger transcription factor, plays a pivotal role in modulating TGF-β-mediated cellular processes such as growth, apoptosis, and differentiation. Recent studies have implicated KLF10 in regulating lipid metabolism and glucose homeostasis. This study aimed to elucidate the precise role of hepatic KLF10 in developing metabolic dysfunction-associated steatohepatitis (MASH) in diet-induced obese mice. METHODS: We investigated hepatic KLF10 expression under metabolic stress and the effects of overexpression or ablation of hepatic KLF10 on MASH development and lipidemia...
April 4, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38548128/interplay-of-cd36-autophagy-and-lipid-metabolism-insights-into-cancer-progression
#9
REVIEW
Yuxuan Yang, Xiaokun Liu, Di Yang, Lianhui Li, Sheng Li, Sen Lu, Ning Li
CD36, a scavenger receptor B2 that is dynamically distributed between cell membranes and organelle membranes, plays a crucial role in regulating lipid metabolism. Abnormal CD36 activity has been linked to a range of metabolic disorders, such as obesity, nonalcoholic fatty liver disease, insulin resistance and cardiovascular disease. CD36 undergoes various modifications, including palmitoylation, glycosylation, and ubiquitination, which greatly affect its binding affinity to various ligands, thereby triggering and influencing various biological effects...
March 26, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38508373/resmetirom-the-first-approved-drug-for-the-management-of-metabolic-dysfunction-associated-steatohepatitis-trials-opportunities-and-challenges
#10
EDITORIAL
Michail Kokkorakis, Chrysoula Boutari, Michael A Hill, Vasilios Kotsis, Rohit Loomba, Arun J Sanyal, Christos S Mantzoros
No abstract text is available yet for this article.
March 18, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38479569/metabolic-plasticity-and-obesity-associated-changes-in-diurnal-postexercise-metabolism-in-mice
#11
JOURNAL ARTICLE
Logan A Pendergrast, Stephen P Ashcroft, Amy M Ehrlich, Jonas T Treebak, Anna Krook, Lucile Dollet, Juleen R Zierath
BACKGROUND: Circadian disruption is widespread and increases the risk of obesity. Timing of therapeutic interventions may promote coherent and efficient gating of metabolic processes and restore energy homeostasis. AIM: To characterize the diurnal postexercise metabolic state in mice and to identify the influence of diet-induced obesity on identified outcomes. METHODS: C57BL6/NTac male mice (6wks of age) were fed a standard chow or high-fat diet for 5 weeks...
March 11, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38462040/the-role-and-mechanisms-of-non-coding-rnas-in-diabetic-peripheral-neuropathy
#12
REVIEW
Yiqian He, Ling Qu
Diabetic peripheral neuropathy (DPN) is a complication of diabetes with a high rate of disability. However, current clinical treatments for DPN are suboptimal. Non-coding RNAs (ncRNAs) are a type of RNAs that are not translated into proteins. NcRNAs perform functions that regulate epigenetic modifications, transcriptional or post-transcriptional regulators of proteins, and thus participate in the physiological and pathological processes of the body. NcRNAs play a role in the progress of DPN by affecting the processes of inflammation, oxidative stress, cellular autophagy or apoptosis...
March 8, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38438106/interleukin-6-classic-and-trans-signaling-utilize-glucose-metabolism-reprogramming-to-achieve-anti-or-pro-inflammatory-effects
#13
JOURNAL ARTICLE
Shilei Xu, Ke-Qiong Deng, Chengbo Lu, Xin Fu, Qingmei Zhu, Shiqi Wan, Lin Zhang, Yu Huang, Longyu Nie, Huanhuan Cai, Qiming Wang, Hao Zeng, Yufeng Zhang, Fubing Wang, Hong Ren, Yu Chen, Huan Yan, Ke Xu, Li Zhou, Mengji Lu, Ying Zhu, Shi Liu, Zhibing Lu
Interleukin (IL)-6 has anti- and pro-inflammatory functions, controlled by IL-6 classic and trans-signaling, respectively. Differences in the downstream signaling mechanism between IL-6 classic and trans-signaling have not been identified. Here, we report that IL-6 activates glycolysis to regulate the inflammatory response. IL-6 regulates glucose metabolism by forming a complex containing signal-transducing activators of transcription 3 (STAT3), hexokinase 2 (HK2), and voltage-dependent anion channel 1 (VDAC1)...
March 2, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38431129/endothelial-cell-serum-and-glucocorticoid-regulated-kinase-1-sgk1-mediates-vascular-stiffening
#14
JOURNAL ARTICLE
Liping Zhang, Zhe Sun, Yan Yang, Austin Mack, Mackenna Rodgers, Annayya Aroor, Guanghong Jia, James R Sowers, Michael A Hill
BACKGROUND: Excessive dietary salt intake increases vascular stiffness in humans, especially in salt-sensitive populations. While we recently suggested that the endothelial sodium channel (EnNaC) contributes to salt-sensitivity related endothelial cell (EC) and arterial stiffening, mechanistic understanding remains incomplete. This study therefore aimed to explore the role of EC-serum and glucocorticoid regulated kinase 1 (SGK1), as a reported regulator of sodium channels, in EC and arterial stiffening...
February 29, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38428673/perturbed-liver-gene-zonation-in-a-mouse-model-of-non-alcoholic-steatohepatitis
#15
JOURNAL ARTICLE
Ye Zhou, Yuanqi Zhao, Marisa Carbonaro, Helen Chen, Mary Germino, Christina Adler, Min Ni, Yuan O Zhu, Sun Y Kim, Judith Altarejos, Zhe Li, Michael E Burczynski, David J Glass, Mark W Sleeman, Ann-Hwee Lee, Gabor Halasz, Xiping Cheng
Liver zonation characterizes the separation of metabolic pathways along the lobules and is required for optimal hepatic function. Wnt signaling is a master regulator of spatial liver zonation. A perivenous-periportal Wnt activity gradient orchestrates metabolic zonation by activating gene expression in perivenous hepatocytes, while suppressing gene expression in their periportal counterparts. However, the understanding as to the liver gene zonation and zonation regulators in diseases is limited. Non-alcoholic steatohepatitis (NASH) is a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis...
February 28, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38412589/corrigendum-to-mortality-in-metabolic-dysfunction-associated-steatotic-liver-disease-a-nationwide-population-based-cohort-study-metabolism-volume-152-march-2024-155789
#16
Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-Ho Lee, Seung Up Kim
No abstract text is available yet for this article.
February 26, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38369056/ketones-provide-an-extra-source-of-fuel-for-the-failing-heart-without-impairing-glucose-oxidation
#17
JOURNAL ARTICLE
Simran Pherwani, David Connolly, Qiuyu Sun, Qutuba G Karwi, Michael Carr, Kim L Ho, Cory S Wagg, Liyan Zhang, Jody Levasseur, Heidi Silver, Jason R B Dyck, Gary D Lopaschuk
BACKGROUND: Cardiac glucose oxidation is decreased in heart failure with reduced ejection fraction (HFrEF), contributing to a decrease in myocardial ATP production. In contrast, circulating ketones and cardiac ketone oxidation are increased in HFrEF. Since ketones compete with glucose as a fuel source, we aimed to determine whether increasing ketone concentration both chronically with the SGLT2 inhibitor, dapagliflozin, or acutely in the perfusate has detrimental effects on cardiac glucose oxidation in HFrEF, and what effect this has on cardiac ATP production...
February 16, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38364901/are-we-underestimating-the-potential-of-neuroactive-drugs-to-augment-neuromotor-function-in-sarcopenia
#18
EDITORIAL
Lucas B R Orssatto, Jacob R Thorstensen, David Scott, Robin M Daly
No abstract text is available yet for this article.
February 14, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38364900/nonlinear-relationship-between-high-density-lipoprotein-cholesterol-and-cardiovascular-disease-an-observational-and-mendelian-randomization-analysis
#19
JOURNAL ARTICLE
Jun-Xiang Chen, Yue Li, Yan-Bo Zhang, Yi Wang, Yan-Feng Zhou, Tingting Geng, Gang Liu, An Pan, Yun-Fei Liao
BACKGROUND: Clinical trials and Mendelian randomization (MR) studies reported null effects of high-density lipoprotein cholesterol (HDLC) on risk of cardiovascular disease (CVD), which might have overlooked a nonlinear causal association. We aimed to investigate the dose-response relationship between circulating HDL-C concentrations and CVD in observational and MR frameworks. METHODS: We included 348,636 participants (52,919 CVD cases and 295,717 non-cases) of European ancestry with genetic data from the UK Biobank (UKB) and acquired genome-wide association summary data for HDL-C of Europeans from the Global Lipids Genetics Consortium (GLGC)...
February 14, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38360130/mortality-risk-in-patients-with-obesity-and-covid-19-infection-a-systematic-review-and-meta-analysis
#20
JOURNAL ARTICLE
Haber Rachelle, Ghezzawi Malak, Puzantian Houry, Haber Marc, Saad Sacha, Ghandour Yara, El Bachour Joseph, Yazbeck Anthony, Hassanieh Ghinwa, Mehdi Celine, Ismail Dima, Abi-Kharma Elias, El-Zein Ola, Khamis Assem, Chakhtoura Marlene, Mantzoros Christos
Obesity is a risk factor for severe respiratory diseases, including COVID-19 infection. Meta-analyses on mortality risk were inconsistent. We systematically searched 3 databases (Medline, Embase, CINAHL) and assessed the quality of studies using the Newcastle-Ottawa tool (CRD42020220140). We included 200 studies from US and Europe, with a mean age of participants 41.8-78.2 years, and a variable prevalence of metabolic co-morbidities of 20-80 %. Exceptionally, one third of the studies had a low prevalence of obesity of <20 %...
February 13, 2024: Metabolism: Clinical and Experimental
journal
journal
23785
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.